|
Therapeutic targeting of clonal hematopoiesis in RUNX1 mutant FPDMM |
University of Pennsylvania |
The RUNX1 Research Program |
|
Creating an Infrastructure for Collaborative Clinical Research and Publication of Consensus Guidelines for RUNX1 Familial Platelet Disorder |
The Cleveland Clinic Foundation |
The RUNX1 Research Program |
|
Mutagenesis and disease progression in RUNX1 mutant blood stem cells is caused by inflammation-induced hyperactive signaling and supraphysiological mitochondrial ROS |
St. Jude Children’s Research Hospital |
The RUNX1 Research Program |
|
Delivering on the Promise of Germline Genetic Testing for RUNX1 Variants |
University of Washington, Seattle |
The RUNX1 Research Program |
|
Using Chemical Genetics to Define the Precise Role of RUNX1 in Transcription and Beyond |
Albert Einstein College of Medicine |
The RUNX1 Research Program |
|
Characterizing Inflammatory Phenotypes Associated with RUNX1 Deficiency |
Dana-Farber Cancer Institute |
The RUNX1 Research Program |
|
Role of PHF6 Mutations in Germline RUNX1 Deficiency Associated Hematopoietic Disorders |
The Regents of the University of California San Francisco |
The RUNX1 Research Program |
|
Assessing Clonal Fitness and Mechanisms of Clonal Evolution in FPD-MN |
Memorial Sloan-Kettering Cancer Center |
The RUNX1 Research Program |
|
Modeling familial platelet disorder associated RUNX1 mutations in mice |
University of Massachusetts Medical School |
The RUNX1 Research Program |
|
Restoring RUNX1 Levels in FPD/AML |
University of Washington, Seattle |
The RUNX1 Research Program |
